Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Wan, Joy ^a   Wang, Shuwei ^a   Haynes, Kevin ^a   Denburg, Michelle R ^b   Shin, Daniel B ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RETINOID; USTEKINUMAB;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY SURFACE AREA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PSORIASIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84888774024     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5961     Document Type: Article

References (42)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24.
3. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
4. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586-92.
5. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 2012;148:995-1000.
6. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556-62.
7. Singh NP, Prakash A, Kubba S, Ganguli A, Singh AK, Sikdar S, et al. Psoriatic nephropathy-does an entity exist? Ren Fail 2005;27:123-7.
8. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011;165:1037-43.
9. Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol 2012;44:509-14.
10. Szepietowski JC, Bielicka E, Wasik F, Kopec W, Szepietowski T. Microalbuminuria as a subclinical marker of renal impairment in subjects with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2000;14:513-4.
11. Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A. Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology 1992;185:93-5.
12. Madeddu P, Ena P, Glorioso N, Cerimele D, Rappelli A. High prevalence of microproteinuria, an early index of renal impairment, in patients with diffuse psoriasis. Nephron 1988;48:222-5.
13. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16:319-23.
14. Kaftan O, Kaftan B, Toppare MF, Eksioglu M. Renal involvement in psoriasis. Dermatology 1996;192:189-90.
15. Cassano N, Vestita M, Panaro M, Carbonara M, Vena GA. Renal function in psoriasis patients. Eur J Dermatol 2011;21:264-5.
16. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
17. Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmel SE, Margolis D, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011;164:602-9.
18. Denburg M, Haynes K, Shults J, Lewis J, Leonard MB. Validation of the Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:S105.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
20. Booth N. What are the Read Codes? Health Libr Rev 1994;11:177-82.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
22. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
23. Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, et al. UK Consensus Conference on Early Chronic Kidney Disease-6 and 7 February 2007. Nephrol Dial Transplant 2007;22:2455-7.
24. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based Study. JAMA Dermatol 2013; Aug 7, doi:10.1001/jamadermatol. 2013.5015.
25. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. National Psoriasis Foundation, 2006. www.psoriasis.org/document.doc?id=354
26. Dommasch ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol 2010;162:835-42.
27. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
28. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010;30:570-81.
29. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. The oncologist 2006;11:694-703.
30. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508.
31. Imai H, Kodama T, Ishino T, Yasuda T, Miura AB, Asakura K, et al. IgA nephropathy associated with hyper IgAnemia, psoriasis or pustulosis and ossification. Clin Nephrol 1995;44:64-8.
32. Zadrazil J, Tichy T, Horak P, Nikorjakova I, Zima P, Krejci K, et al. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy'. J Nephrol 2006;19:382-6.
33. Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol 1998;18:425-9.
34. Kaji T, Tsukada Y, Shimada A, Miyamoto K, Yoshida M, Yano S, et al. Membranous nephropathy associated with psoriasis vulgaris. Clin Nephrol 1994;42:63-4.
35. Sirolli V, Bonomini M. Glomerulopathies associated with psoriasis: a report of three cases. Nephron 2000;86:89-90.
36. Kim M, Ko Y, Yeo UC, Kim Y, Oh H. Psoriasis and glomerulonephritis. Clin Exp Dermatol 1998;23:295-6.
37. Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol 2000;6:6-9.
38. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009;160:1048-56.
39. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6.
40. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
41. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ 2013;347:f4298.
42. Office for National Statistics. Population estimates by ethnic group 2002-2009. Statistics Bulletin, May 2011.